Inventor
WATSON DAVID WYN
GB20 patents
⚠️ This page may combine multiple inventors who share the name “WATSON DAVID WYN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ASTRAZENECA AB
15 patentsUS10287258B2May 14, 2019
Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors
ASTRAZENECA AB18 citations97
US9522894B2Dec 20, 2016
Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors
ASTRAZENECA AB25 citations97
US11773069B2Oct 3, 2023
Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors
ASTRAZENECA AB6 citations94
US11117874B2Sep 14, 2021
Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors
ASTRAZENECA AB15 citations93
US10669245B2Jun 2, 2020
Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides dipeptidyl peptidase 1 inhibitors
ASTRAZENECA AB16 citations93
US12054465B2Aug 6, 2024
Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors
ASTRAZENECA AB3 citations85
US11814359B2Nov 14, 2023
Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors
ASTRAZENECA AB4 citations85
US11680049B2Jun 20, 2023
Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors
ASTRAZENECA AB5 citations85
US11673872B2Jun 13, 2023
Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors
ASTRAZENECA AB5 citations85
US11673871B2Jun 13, 2023
Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors
ASTRAZENECA AB5 citations85
US11667615B2Jun 6, 2023
Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors
ASTRAZENECA AB5 citations85
US11655221B2May 23, 2023
Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors
ASTRAZENECA AB5 citations85
US11655224B2May 23, 2023
Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors
ASTRAZENECA AB5 citations85
US11655223B2May 23, 2023
Certain (2S)-N-[(1 s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors
ASTRAZENECA AB5 citations85
US11655222B2May 23, 2023
Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors
ASTRAZENECA AB5 citations84
ASTEX THERAPEUTICS LTD
5 patentsUS10544132B2Jan 28, 2020
Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity
ASTEX THERAPEUTICS LTD10 citations82
US10526311B2Jan 7, 2020
Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity
ASTEX THERAPEUTICS LTD6 citations82
US11261171B1Mar 1, 2022
Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity
ASTEX THERAPEUTICS LTD2 citations71
US10981898B2Apr 20, 2021
Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity
ASTEX THERAPEUTICS LTD4 citations71
US12071429B2Aug 27, 2024
Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity
ASTEX THERAPEUTICS LTD0 citations60